Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study

The Lancet Oncology ◽

10.1016/s1470-2045(19)30088-9 ◽

2019 ◽

Vol 20 (6) ◽

pp. 827-836 ◽

Author(s):

Kohei Shitara ◽

Hiroji Iwata ◽

Shunji Takahashi ◽

Kenji Tamura ◽

Haeseong Park ◽

...

Keyword(s):

Gastric Cancer ◽

Phase 1 ◽

Her2 Positive ◽

Phase 1 Study ◽

Expansion Phase

Download Full-text

Faculty Opinions recommendation of Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735680776.793565215 ◽

2019 ◽

Author(s):

Scott Kaufmann

Keyword(s):

Gastric Cancer ◽

Phase 1 ◽

Her2 Positive ◽

Phase 1 Study ◽

Expansion Phase

Download Full-text

Faculty Opinions recommendation of Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735680777.793565214 ◽

2019 ◽

Author(s):

Scott Kaufmann

Keyword(s):

Breast Cancer ◽

Phase 1 ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 1 Study ◽

Expansion Phase ◽

Her2 Positive Breast Cancer ◽

Previously Treated ◽

Positive Breast Cancer

Download Full-text

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

The Lancet Oncology ◽

10.1016/s1470-2045(19)30097-x ◽

2019 ◽

Vol 20 (6) ◽

pp. 816-826 ◽

Author(s):

Kenji Tamura ◽

Junji Tsurutani ◽

Shunji Takahashi ◽

Hiroji Iwata ◽

Ian E Krop ◽

...

Keyword(s):

Breast Cancer ◽

Phase 1 ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 1 Study ◽

Expansion Phase ◽

Her2 Positive Breast Cancer ◽

Previously Treated ◽

Positive Breast Cancer

Download Full-text

Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer

Annals of Oncology ◽

10.1093/annonc/mdy048.005 ◽

2018 ◽

Vol 29 ◽

pp. iii8 ◽

Author(s):

M. Pegram ◽

E. Hamilton ◽

A.R. Tan ◽

A.M. Storniolo ◽

N. Elgeioushi ◽

...

Keyword(s):

Gastric Cancer ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Her2 Positive ◽

Phase 1 Study ◽

Drug Conjugate ◽

Download Full-text

Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Local Advanced or Metastatic, HER2 Positive Breast Cancer.

Case Medical Research ◽

10.31525/ct1-nct03944499 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Solid Tumors ◽

Phase 1 ◽

Advanced Solid Tumors ◽

Her2 Positive ◽

Phase 1 Study ◽

Her2 Positive Breast Cancer ◽

Local Advanced ◽

Positive Breast Cancer

Download Full-text

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

JTO Clinical and Research Reports ◽

10.1016/j.jtocrr.2020.100093 ◽

2020 ◽

Vol 1 (4) ◽

pp. 100093

Author(s):

Peter W. Szlosarek ◽

Melissa M. Phillips ◽

Iuliia Pavlyk ◽

Jeremy Steele ◽

Jonathan Shamash ◽

...

Keyword(s):

Phase 1 ◽

Resistance Mechanisms ◽

Argininosuccinate Synthetase ◽

Phase 1 Study ◽

Expansion Phase

Download Full-text

SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.05.055 ◽

2021 ◽

Vol 32 ◽

pp. S215-S216

Author(s):

H. Chung ◽

K. Lee ◽

W. Kim ◽

J. Gainor ◽

N. Lakhani ◽

...

Keyword(s):

Phase 1 ◽

Gastroesophageal Junction ◽

Second Line ◽

Her2 Positive ◽

Phase 1 Study ◽

Gastroesophageal Junction Cancer

Download Full-text

Biomarker Analysis of a Phase 1 Study of Mm-111, a Bispecific Her2/Her3 Antibody Fusion Protein, in Combination with Multiple Treatment Regimens in Patients with Advanced Her2 Positive Solid Tumors

Annals of Oncology ◽

10.1093/annonc/mdu326.75 ◽

2014 ◽

Vol 25 ◽

pp. iv81

Author(s):

A. Kudla ◽

B. Adiwijaya ◽

V. Paragas ◽

D. Richards ◽

F. Braiteh ◽

...

Keyword(s):

Fusion Protein ◽

Solid Tumors ◽

Phase 1 ◽

Her2 Positive ◽

Phase 1 Study ◽

Multiple Treatment ◽

Treatment Regimens ◽

Biomarker Analysis ◽

Antibody Fusion Protein

Download Full-text

Abstract P1-18-36: The safety, tolerability, and pharmacokinetics of BAT8001 in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer: An open-label, dose-up, phase 1 study

10.1158/1538-7445.sabcs19-p1-18-36 ◽

2020 ◽

Author(s):

Shusen Wang ◽

Ruoxi Hong ◽

Liye Wang ◽

Fei Xu ◽

Wen Xia

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Her2 Positive ◽

Phase 1 Study ◽

Epidermal Growth

Download Full-text

Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study

The Lancet Haematology ◽

10.1016/s2352-3026(20)30208-8 ◽

2020 ◽

Vol 7 (9) ◽

pp. e649-e659 ◽

Author(s):

Jean-Marie Michot ◽

Reda Bouabdallah ◽

Umberto Vitolo ◽

Jeanette K Doorduijn ◽

Gilles Salles ◽

...

Keyword(s):

B Cell ◽

Hodgkin Lymphoma ◽

Dose Escalation ◽

Phase 1 ◽

Phase 1 Study ◽

Expansion Phase ◽

Non Hodgkin Lymphoma

Download Full-text